{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Randomized+diabetes+therapy",
    "query": {
      "intervention": "Randomized diabetes therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 797,
    "total_pages": 80,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Randomized+diabetes+therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T12:21:36.196Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00108485",
      "title": "Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Kidney Failure, Chronic",
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Extended release niacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2005-04",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-06-22",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108485"
    },
    {
      "nct_id": "NCT01774968",
      "title": "Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Human Regular U-500 Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 325,
      "start_date": "2013-02",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2015-09-22",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 35,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01774968"
    },
    {
      "nct_id": "NCT01240759",
      "title": "Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "S-707106 Dose A",
          "type": "DRUG"
        },
        {
          "name": "S-707106 Dose B",
          "type": "DRUG"
        },
        {
          "name": "S-707106 Dose C",
          "type": "DRUG"
        },
        {
          "name": "Placebo A tablet",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 218,
      "start_date": "2010-10",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2018-05-15",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01240759"
    },
    {
      "nct_id": "NCT03830281",
      "title": "A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Ultra-Rapid Lispro",
          "type": "DRUG"
        },
        {
          "name": "Insulin Lispro",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 471,
      "start_date": "2019-02-14",
      "completion_date": "2020-01-06",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 32,
      "location_summary": "Concord, California • Fresno, California • Greenbrae, California + 28 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03830281"
    },
    {
      "nct_id": "NCT04603937",
      "title": "A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "KSI-301",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kodiak Sciences Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 459,
      "start_date": "2020-09-30",
      "completion_date": "2023-08-31",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04603937"
    },
    {
      "nct_id": "NCT00968708",
      "title": "Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Alogliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5380,
      "start_date": "2009-09",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 292,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Cottonwood",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968708"
    },
    {
      "nct_id": "NCT04880291",
      "title": "First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Diseases",
        "Diabetic Nephropathies",
        "Diabetes Complications",
        "Diabetes Mellitus",
        "Endocrine System Diseases"
      ],
      "interventions": [
        {
          "name": "GFB-024",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Goldfinch Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 39,
      "start_date": "2021-05-05",
      "completion_date": "2022-02-08",
      "has_results": false,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04880291"
    },
    {
      "nct_id": "NCT01498185",
      "title": "BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 171,
      "start_date": "2012-02",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2017-02-10",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 12,
      "location_summary": "Chula Vista, California • San Diego, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498185"
    },
    {
      "nct_id": "NCT02688933",
      "title": "A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "HOE901-U300 (Insulin Glargine 300 U/ml)",
          "type": "DRUG"
        },
        {
          "name": "Lantus (Insulin Glargine 100 U/ml)",
          "type": "DRUG"
        },
        {
          "name": "Mandated back ground therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 638,
      "start_date": "2016-05-05",
      "completion_date": "2017-06-19",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 99,
      "location_summary": "Little Rock, Arkansas • Concord, California • Escondido, California + 80 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02688933"
    },
    {
      "nct_id": "NCT01822925",
      "title": "Study of DA-9801 to Treat Diabetic Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Neuropathy"
      ],
      "interventions": [
        {
          "name": "DA-9801 300mg",
          "type": "DRUG"
        },
        {
          "name": "DA-9801 600mg",
          "type": "DRUG"
        },
        {
          "name": "DA-9801 900mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeuroBo Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 128,
      "start_date": "2013-11",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2020-03-20",
      "last_synced_at": "2026-09-02T12:21:36.196Z",
      "location_count": 14,
      "location_summary": "Lakewood, California • Walnut Creek, California • Milford, Connecticut + 10 more",
      "locations": [
        {
          "city": "Lakewood",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01822925"
    }
  ]
}